Aditya Birla Sun Life Pharma and Healthcare Fund-Regular-Growth
💡 Why Pick This Fund? Quantitative Strengths & Watch-outs
- Outperformed category benchmark in 61% of historical 3-year rolling periods.
- Strong capital defense: downside capture of 50% limits losses during market corrections.
- Generated +9.1% annualized alpha (excess return) over its benchmark.
- Cost-efficient: expense ratio of 2.27% is lower than category median (2.52%).
- Equities carry market risk; returns fluctuate and recommended investment horizon is 5+ years.
Key Statistics vs Category Median
Trailing Returns Comparison
| Period | Fund Return | Category Median | Difference |
|---|---|---|---|
| 1 Month | +7.24% | +6.32% | +0.92% |
| 3 Months | +0.90% | -0.20% | +1.10% |
| 6 Months | +11.49% | +5.98% | +5.51% |
| 1 Year | +19.52% | +3.90% | +15.62% |
| 3 Years CAGR | +19.30% | +13.23% | +6.07% |
| 5 Years CAGR | +14.56% | +10.72% | +3.84% |
| 7 Years CAGR | +19.97% | +15.35% | +4.62% |
| Since Inception | +19.51% | - | - |
📈 Monthly SIP vs Bank Fixed Deposit (FD) Replay
See how a regular monthly SIP in Aditya Birla Sun Life Pharma and Healthcare Fund compares against a standard 7.0% p.a. Bank Fixed Deposit.
Calendar Year Returns
| Year | Fund | Category Median | Gap |
|---|---|---|---|
| 2026 | +21.15% | +4.03% | +17.12% |
| 2025 | -4.30% | +1.43% | -5.73% |
| 2024 | +35.79% | +20.41% | +15.38% |
| 2023 | +37.67% | +30.70% | +6.97% |
| 2022 | -12.68% | +1.66% | -14.34% |
| 2021 | +19.54% | +30.31% | -10.77% |
| 2020 | +53.84% | +13.54% | +40.30% |
Daily Rolling Returns Summary
| Rolling Window | Minimum | Average | Median | Maximum | % Positive | % Beating Proxy |
|---|---|---|---|---|---|---|
| 1-Year Rolling | -16.87% | +21.06% | +16.17% | +69.83% | 79.0% | 52.8% |
| 3-Year Rolling | +10.43% | +17.94% | +18.14% | +25.91% | 100.0% | 60.7% |
| 5-Year Rolling | +11.50% | +17.79% | +16.36% | +27.21% | 100.0% | 52.1% |
Risk Profile & Deepest Drawdowns
Deepest Market Corrections (Depth >= 10%)
| Peak Date | Trough Date | Fall Depth | Months to Bottom | Recovery Period |
|---|---|---|---|---|
| 2021-09-16 | 2022-06-17 | -21.4% | 9 months | 13 months |
| 2020-02-13 | 2020-03-23 | -20.5% | 1 months | 1 months |
| 2024-10-09 | 2025-02-28 | -16.3% | 5 months | 14 months |
Portfolio & Asset Allocation
Statutory Asset Allocation Mandate (SEBI / SID)
| Instrument Category | Permitted Allocation Range |
|---|---|
| Under normal circumstances, the asset allocation of the Scheme will be as follows: | Per Scheme Mandate |
| Equities & Equity related instruments of companies in the Pharma, Healthcare | Per Scheme Mandate |
| and Allied sectors | 80%-100% |
| Other Equities & Equity related instruments | 0%-20% |
| Units issued by InvITs | 0%-10% |
| Liquid* and Money market instruments | 0%-20% |
| Units of Mutual Funds^ | 0%-20% |
| *As defined by SEBI. | Per Scheme Mandate |
| ^Overnight, Liquid and Money Market Funds. | Per Scheme Mandate |
Investment Objective & Strategy
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
ℹ️ Detailed monthly stock-level holdings for this scheme are updated periodically from asset management company statutory disclosures.
Fund Size Position
Currently managing Rs 1,154 cr (AMFI Daily Fund AUM as of 2026-11-11). Positioned as comfortable relative to Sectoral / Thematic schemes.
Fund Management
Cost & Capital Gains Taxation
From April 2026 the total expense ratio includes brokerage, transaction costs and statutory levies on top of the base fee.
Equity-oriented schemes: 20% short-term capital gains tax if sold within 12 months; 12.5% long-term capital gains tax on gains exceeding ₹1.25 lakh per financial year when held for more than 12 months.
Closest Sectoral / Thematic Peers by Rank
| Scheme | Score | 3Y Return | Expense | Downside | Fund Size | Compare |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life International Equity Fund | 5.8 | +20.53% | 2.55% | -28.3% | Rs 337 cr | Compare → |
| LIC MF Healthcare Fund | 7.1 | +20.28% | 2.72% | 59.8% | Rs 101 cr | Compare → |
| DSP Healthcare Fund | 8.0 | +20.31% | 2.04% | 53.2% | Rs 3,946 cr | Compare → |
| Kotak Pioneer Fund | 7.3 | +18.33% | 1.90% | 77.2% | Rs 4,405 cr | Compare → |
| Nippon India Taiwan Equity fund | 7.2 | +45.47% | 2.39% | -77.2% | Rs 806 cr | Compare → |
Frequently Asked Questions about Aditya Birla Sun Life Pharma and Healthcare Fund
What is the expense ratio of Aditya Birla Sun Life Pharma and Healthcare Fund?
Aditya Birla Sun Life Pharma and Healthcare Fund has a total expense ratio (TER) of 2.27% with a base expense ratio of 1.88%, compared to the Sectoral / Thematic category median of 2.52%.
Who manages Aditya Birla Sun Life Pharma and Healthcare Fund?
Aditya Birla Sun Life Pharma and Healthcare Fund is managed by Dhaval Shah (tenure: 7.3 years since 2019-07-11).
What are the historical returns of Aditya Birla Sun Life Pharma and Healthcare Fund?
Aditya Birla Sun Life Pharma and Healthcare Fund delivered a 3-year CAGR of 19.3% and a 5-year CAGR of 14.56%. Its 1-year return stands at +19.52%.
How large is Aditya Birla Sun Life Pharma and Healthcare Fund?
Aditya Birla Sun Life Pharma and Healthcare Fund manages assets of Rs 1,154 cr, placing it in the 'comfortable' size band relative to Sectoral / Thematic peers.
How is Aditya Birla Sun Life Pharma and Healthcare Fund scored on MFIQ?
Aditya Birla Sun Life Pharma and Healthcare Fund holds an MFIQ Score of 7.4/10 (Good), based on a category percentile composite across returns, risk, consistency, and cost.
How risky is Aditya Birla Sun Life Pharma and Healthcare Fund?
Aditya Birla Sun Life Pharma and Healthcare Fund has an official SEBI riskometer rating of Very High. Over the analyzed period, its annualized standard deviation is 13.00% with a maximum historical drawdown of -21.38%.